Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

2026 & BEYOND MASTER PLAN

Core Narrative – LPBI Group’s

Integrated Value Proposition

Leaders in Pharmaceutical Business Intelligence (LPBI) Group has built a unique 9 GB private multimodal corpus and a proprietary 15-part Composition of Methods (COM) Tool Factory specifically engineered for domain-aware AI in Health.

Macroenvironment Validation The AI transformation of life sciences is accelerating dramatically. NVIDIA is rapidly expanding its BioNeMo platform with major pharmaceutical partners Roche and Eli Lilly, while IQVIA has already deployed more than 150 agentic AI systems across 19 of the top 20 pharmaceutical companies. At the same time, the genomics sector continues its strong valuation growth, investment in AI drug discovery is surging across generative design, target validation, and clinical optimization, and the broader Elon Musk ecosystem (Tesla–SpaceX–xAI) is converging toward unprecedented scale. Industry leaders are shifting focus from isolated molecules to sophisticated models and ultimately to fully recursive discovery factories. Yet this rapid adoption also brings heightened risks, as demonstrated by the recent accidental leak of Anthropic’s secret “Mythos” model through a simple configuration error.

In this dynamic environment, LPBI Group’s integrated ecosystem — the 9 GB private multimodal corpus, the flagship AJAUS (COM Part 14) autonomous updating system with human-in-the-loop governance, and 14 years of expert human curation — delivers the critical high-provenance, causally structured intelligence layer that these powerful platforms urgently need.

Three Interdependent Pillars LPBI Group offers a complete, production-ready ecosystem for domain-aware AI in Health, built on three synergistic pillars:

• COM Tool Factory (especially Part 14 – AJAUS): The world’s first autonomous multi-agent journal article updating system with objective-driven orchestration and human-in-the-loop governance.
• Trainable Data: A unique 9 GB private multimodal corpus, 13 Hidden Gems, and 15 “Articles of Note” collections that provide causally structured, high-provenance biomedical intelligence.
• Human Signal + Expert Curation: 14 years of deep domain expertise by physicians, scientists, and clinical experts who ensure quality, causality, and clinical relevance.

Flagship Development COM Part 15 – Rosetta Stone Ontology introduces the proprietary Rosetta Stone Ontology, a structured translational framework that maps the full continuum from disease indications to therapeutics and corrective interventions. It enables the creation of recursive discovery factories and gives Grok 4.20 (and future models) a decisive advantage: the ability to reason at the level of clinical mechanisms of action rather than relying solely on molecule-level combinatorics. All COM 15-Parts are described in Section 8, below.

2026 Context & Achievements 2026 is the first year following the successful completion of LPBI Group’s 2.0 Plan (2021–2025). After 14 years of continuous operations and remarkable achievements, the Master Plan for 2026 & Beyond outlines a clear quest for Transfer of Ownership of LPBI Group’s Portfolio of IP Assets. This portfolio comprises multimodal TRAINABLE Data Assets, acknowledged e-Reputation, and considerable premium INTANGIBLE Assets.

Chiefly, COM Parts 1-9 were developed since venture inception and completed by end of 2025. Parts 10–15 of COM were created in 2026.

A fascinating guided journey will take you through the new potential of the AI Era, where proprietary expert-curated trainable data assets are increasingly sought after and the premise of Small Language Models in Healthcare is just emerging.

LPBI’s 9 GB private multimodal corpus + 15-part COM Tool Factory provides the high-provenance, causally structured data moat that powers the next generation of AI drug discovery platforms and foundation models — directly addressing the proprietary data needs highlighted in recent industry analyses.

Key Milestones (as of April 6, 2026)

I. The Journal PharmaceuticalIntelligence.com was launched in April 2012 All-time stats:

1. Journal Article Views: 2,554,000
2. Website Visitors: 1,589,469
3. Scientific Articles published: 6,285
4. Journal Ontology: 757 Categories of Research

II. BioMed e-Series was launched in October 2012

1. The 1st book was published in June 2013, and
2. The 48th Book was published in December 2023.

Tailored presentations for Pharma/Biotech, Hyperscalers, Grok 4.20 Pivot, and PE/VC investors are available upon qualified request.

• 1. Founder’s Vision

• 2. LPBI Group’s History

• 3. 2.0 LPBI – 2021-2026 Reality

• 4. Journal PharmaceuticalIntelligence.com

• 5. BioMed e-Series

• 6. Portfolio of IP Assets

• 7. Knowledge PORTALS System (KPS)

• 8. TOOL FACTORY, Composition of Methods (COM), IP Asset Class IV

• 9. Total Valuation & Waterfall

• 10. Joint Articles & Proof Points

• 11. Future Scenarios & Exit Path

• 12. Investor Relations & Next Steps

This page has the following sub pages.

• 1. Founder’s Vision
• 2. LPBI Group’s History
• 3. 2.0 LPBI – 2021-2026 Reality
• 4. Journal PharmaceuticalIntelligence.com
• 5. BioMed e-Series
• 6. Portfolio of IP Assets
• 7. Knowledge PORTALS System (KPS)
• 8. TOOL FACTORY, Composition of Methods (COM), IP Asset Class IV
• 9. Total Valuation & Waterfall
• 10. Joint Articles & Proof Points
• 11. Future Scenarios & Exit Path
• 12. Investor Relations & Next Steps
• Version A – Methodologies & Tool Factory
• Version B – Trainable Multimodal Data
• Version C – Emphasis on Human Signal + Expert Curation
• >>>>>>>>>>>> ABC: Pharma / Biotech >>>>>>>>>>>>
• >>>>>>>> ABC: Hyperscalers and Frontier Modelers >>>>>>>
• >>>>>>>>> Grok 4 aids Exit: Focus Medicine Grok 4.20 >>>>>>>>>
• >>>>>>>>> Grok 4 aids Exit: Focus Hyperscaler Parents >>>>>>>>>
• >> PE/VC, Holding Companies and Institutional Investors >>